Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-108459 IV in Atrial Fibrillation
jRCT2080222398Phase 1
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OPC-108459 in Atrial fibrillation (AFib) (5 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of OPC-108459, Pharmacokinetics of OPC-108459 and 1 more.
02
Drugs
OPC-108459
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on jRCT2080222398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222398.